Our Capabilities
R&D, Process & Quality
From route scouting through process scale-up to final analytical release — we coordinate every stage of chiral intermediate supply with the precision pharmaceutical customers demand.
R&D Capabilities
Our network of specialist CDMO partners maintains dedicated chiral chemistry teams focused on developing and optimizing synthesis routes for demanding intermediates. Expertise spans asymmetric catalysis, biocatalytic methods and resolution techniques applied to complex chiral centers.
Process Development
We coordinate custom process development across three primary methodologies: asymmetric synthesis (catalytic enantioselective transformations), enzymatic catalysis (immobilised enzyme or whole-cell systems) and chiral resolution (diastereomeric salt crystallisation and preparative chromatography). Routes are selected to maximise ee while controlling cost and scalability.
QC & Analytics
Every batch undergoes a defined analytical protocol: optical rotation measurement, ee determination by chiral HPLC or GC, full impurity profiling (known and unknown impurities), and a batch Certificate of Analysis reviewed against JP/EP pharmacopoeia specification limits before release.
Process Development Methods
Synthesis route selection is driven by the specific structural requirements of each intermediate. We apply whichever method delivers the best balance of enantioselectivity, yield and commercial viability.
Transition-metal and organocatalytic enantioselective reactions delivering ee ≥ 99% in a single synthetic step without resolution waste.
Immobilised lipase, ketoreductase and transaminase systems enable green, high-selectivity transformations at mild conditions, ideal for sensitive functional groups.
Diastereomeric salt formation and preparative chiral chromatography for racemate resolution; mother liquor racemisation recycles the unwanted enantiomer to maximise atom economy.
Analytical Release Protocol
Our quality team — led by our founder with a pharmaceutical synthesis background — reviews COA data against pharmacopoeia limits before any shipment is authorised.
- Optical Rotation (polarimetry)
- ee Determination (chiral HPLC / GC)
- Impurity Profiling (LC-MS / GC-MS)
- Certificate of Analysis (COA) per batch
- JP / EP Pharmacopoeia compliance check
Need a custom synthesis route or a specific intermediate?
Request a Quote →